Boston, Massachusetts—Nov. 14, 2019—Dyad Medical, a leading provider of deep learning medical image analysis software, announced that it has joined the new Qualcomm® XR Enterprise Program (XEP). The new program allows enterprise solution providers to be part of a global community that offers access to technical support resources, promotional opportunities, co-marketing, joint planning and business development and matchmaking with other members for the collective goal of accelerating the enterprise XR segment to help increase operational efficiencies, worker satisfaction & safety and impact the bottom line.
Dyad Medical develops cardiac medical image interpretation software platform. Dyad Medical’s technology incorporates artificial intelligence to investigate image content and combines it with state-of-the-art visualization technologies to visualize analysis results, guide the clinicians and support diagnostic decision making.
“We’re thrilled to join the exceptional list of startups in the XR Enterprise program, which supports our vision of streamlining patient treatment, reducing diagnostic error rates and making image analysis more accessible,” said Ronny Shalev, PhD, cofounder and CEO of Dyad Medical. “Joining the program will help support our goal for expansion into new markets and help ensure our AI offering continues to be ahead of the curve.”
About Dyad Medical
Dyad Medical is a pioneer in the development of deep learning architectures enabling quick and accurate medical image analysis and interpretation. With a platform developed by data scientists, machine learning practitioners, and medical experts, Dyad Medical is researching and developing analysis algorithms of heart images generated by a variety of data sources improving diagnostic accuracy.
Qualcomm invents breakthrough technologies that transform how the world computes, connects and communicates. When we connected the phone to the Internet, the mobile revolution was born. Today, our inventions are the foundation for life-changing products, experiences, and industries. As we lead the world to 5G, we envision this next big change in cellular technology spurring a new era of intelligent, connected devices and enabling new opportunities in connected cars, remote delivery of health care services, and the IoT — including smart cities, smart homes, and wearables. Qualcomm Incorporated includes our licensing business, QTL, and the vast majority of our patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, all of our engineering, research and development functions, and all of our products and services businesses, including, the QCT semiconductor business. For more information, visit Qualcomm’s website, OnQ blog, Twitter and Facebook pages.
Qualcomm and Snapdragon are trademarks of Qualcomm Incorporated, registered in the United States and other countries.
Qualcomm Snapdragon is a product of Qualcomm Technologies, Inc. and/or its subsidiaries. The Qualcomm Advantage Network is a program of Qualcomm Technologies, Inc. and/or its subsidiaries.
Find out more at
www.dyadmed.com and follow us on Twitter and Linkedin.
Contact about this news:
Dyad Medical, Inc.
Ronny Shalev, PhD